Global Amniotic Products Market Size Report, 2022 - 2030
Amniotic Products Market Share, Size, Trends, Industry Analysis Report, 2022 - 2030

Amniotic Products Market Share, Size, Trends, Industry Analysis Report, By Application (Wound Care, Orthopedics, Ophthalmology, Others); By End-Use (Hospitals & ASCs, Others); By Type; By Region; Segment Forecast, 2022 - 2030

  • Published Date:Jan-2022
  • Pages: 112
  • Format: PDF
  • Report ID: PM2217
  • Base Year: 2021
  • Historical Data: 2018 - 2020

Report Outlook

The global amniotic products market was valued at USD 748.4 million in 2021 and is expected to grow at a CAGR of 8.4% during the forecast period. The progressive market growth can be attributed to the rising number of trauma and accident cases globally, along with the rising awareness regarding the benefits provided by amniotic products.

Amniotic Products Market SizeKnow more about this reportrequest for sample pages

The growth in the number of burn incidences globally is further anticipated to drive the growth of the amniotic products market. According to the Global Burden of Diseases, in 2019, over 89 million cases of burn injuries were recorded globally. The anti-scarring and inflammatory properties of the amniotic membrane help a lot in reducing the inflammation & discomfort caused by the burns. 

The outbreak of the COVID-19 had a negative influence on the overall amniotic products industry in 2021 on account of the lockdowns across nations. As the lockdowns deny wound care services and postpone/cancel elective surgeries. The elective surgeries were postponed/ canceled during the outbreak in order to redirect or reserve the available resources & capacities such as patient care professionals and hospital beds for Covid-19 patient care.

Additionally, due to lockdowns, patients were not able to visit clinics, hospitals, or OPDs. Thus, the temporary denial of various non-emergency healthcare services limited the growth of the amniotic products market during the covid-19 outbreak period. However, as the lockdowns are down, the demand for amniotic products is on a rise.

Amniotic Products Market

Know more about this reportrequest for sample pages

Industry Dynamics 

Growth Drivers
The rising incidence of burn injuries globally is anticipated to drive the demand for wound care biologics. According to WHO, burns are very high across various African & Southeast Asian countries such as India, Bangladesh, and Nepal, among others. For instance, over 173,000 children suffer severe or moderate burns throughout Bangladesh every year. Moreover, in Nepal, burns account for over 5% of all disabilities.

Furthermore, the implementation of 21st-century cures across emerging economies and the growing demand for regenerative medicine and stem cell research are predicted to boost the amniotic products industry growth. The 21st-century cures act was enacted as a law by the US government in December 2016. This main objective is to advance regenerative medicine research along with medical innovation. The implementation of this law has stimulated R&D activities across the field of regenerative medicine along with the fast-track approval of various new regenerative therapies and medical products.

Report Segmentation

The market is primarily segmented on the basis of type, application, end-use, and region.

By Type

By Application

By End-Use

By Region

  • Membranes
    • Cryopreserved Membranes
    • Dehydrated Membranes
  • Suspensions
  • Wound Care
  • Orthopedics
  • Ophthalmology
  • Others
  • Hospitals & ASCs
  • Others
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Know more about this reportrequest for sample pages

Insight by Type

The membranes segment accounts for the largest share of the global amniotic products market. The huge share of this segment can be attributed to the greater effectiveness of membranes to suspensions. The growing use of amniotic membranes for various conditions pertaining to ophthalmology, such as corneal surface lesions, limbal stem cell generation, and retinal detachments, is anticipated to provide exponential growth of the segment.

Moreover, the suspensions segment is likely to grow a progressive CAGR in the approaching years. The growth of the segment can be attributed to the growing use of amniotic suspensions as an effective non-operative treatment for symptomatic knee osteoarthritis. Furthermore, studies regarding the safety and efficacy of amniotic suspension for symptomatic osteoarthritis are expected to drive the growth of the segment.

In July 2021, Organogenesis Inc. announced ReNu, an amniotic suspension. The company further got approval from FDA (US) by granting the regenerative medicine therapy designation for the use in knee osteoarthritis. Developments such as these by the industry players are expected to drive the growth of the segment.

Insight by Application

The wound care segment is recorded with the largest revenue share in 2021 and is expected to lead the amniotic products market in the forecasting years. The huge share of the segment can be attributed to the rising number of surgical & traumatic wounds and burns. Further, the growing need for advanced treatment with better efficiency and safety is anticipated to drive the growth of the segment.

The developments made by key players in the amniotic products industry are further anticipated to drive the growth of the segment. For instance, in 2019, Smith & Nephew, based in the UK, acquired Orisis Therapeutics for over USD 660 million in order to develop regenerative medicine products for wound care.

The ophthalmology segment is projected to witness progressive growth in the global market. The growth of the segment can be attributed to the growing use of tissue-based products across ophthalmic surgeries for their fast healing and inflammation-reducing properties.

Geographic Overview

Geographically, North America is accounted with the largest revenue share in the global market in 2021, owing to the huge prevalence of target disease, rising awareness regarding advanced treatment options, the increasing geriatric population across the region, and the solid presence of various key market players of the market.

Nowadays, on account of the rising geriatric population, there is an increase in the number of ophthalmic surgeries performed across the region, and the wide use of amniotic membranes for ophthalmic surgeries is expected to boost the growth of the market. Furthermore, the introduction of regulatory laws such as the 21st Century Cures Act by the US government ensures progressive growth during the forecast period.

Moreover, Asia Pacific is expected to grow at the highest CAGR across the globe in the approaching years. Various developing countries across the region are focusing on boosting their research in regenerative medicine. This aspect is estimated to have a positive impact on the growth of the market in the region. Additionally, fast-track approvals of novel regenerative products/medicines along with the introduction of various initiatives and acts are anticipated to drive the growth of the market.

Competitive Insight

Some of the major players operating the global market include Applied Biologics, Celularity Inc., Integra Lifesciences, Katena Products, Inc., Lucina Biosciences, Mimedx, Next Biosciences, Nuvision Biotherapies Ltd, Organogenesis Inc., Skye Biologics Holdings, LLC, Smith & Nephew Plc, Stimlabs LLC, Stryker, Surgenex, Tides Medical, Tissuetech, Inc., Ventris Medical, LLC, and Vivex Biologics.

Amniotic Products Market Report Scope

Report Attributes

Details

Market size value in 2021

USD 748.4 million

Revenue forecast in 2030

USD 1,527.2 million

CAGR

8.4% from 2022 - 2030

Base year

2021

Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Segments covered

By Type, By Application, By End-Use, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Key companies

Applied Biologics, Celularity Inc., Integra Lifesciences, Katena Products, Inc., Lucina Biosciences, Mimedx, Next Biosciences, Nuvision Biotherapies Ltd, Organogenesis Inc., Skye Biologics Holdings, LLC, Smith & Nephew Plc, Stimlabs LLC, Stryker, Surgenex, Tides Medical, Tissuetech, Inc., Ventris Medical, LLC, and Vivex Biologics.